19.65

3.42% +0.65

Kura Oncology Inc (KURA)

Overview News Price History Option Chain Discussions Forecast

Kura Oncology Inc stock is currently priced at $19.65, with a 24-hour trading volume of 556.07K. It has seen a +3.42% increased in the last 24 hours and a -3.77% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $18.73 pivot point. If it approaches the $19.99 resistance level, significant changes may occur.

Previous Close:

$19.00

Open:

$19.2

24h Volume:

556.07K

Market Cap:

$1.50B

Revenue:

Net Income/Loss:

$-152.63M

P/E Ratio:

-9.5854

EPS:

-2.05

Net Cash Flow:

$-124.99M

1W Performance:

+12.09%

1M Performance:

-3.77%

6M Performance:

+148.73%

1Y Performance:

+93.98%

1D Range:

$18.95

$19.71

52W Range:

$7.41

$24.17

Kura Oncology Inc Stock (KURA) Company Profile

Name

Kura Oncology Inc

Sector

Healthcare (1191)

Industry

Biotechnology (688)

Phone

858-500-8800

Address

3033 Science Park Road, Suite 220, San Diego, CA

Employee

Twitter

@kuraoncology

Next Earnings Date

2024-05-02

Latest SEC Filings

KURA's Discussions on Twitter

Kura Oncology Inc Stock (KURA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-22-23	Initiated	Mizuho	Buy
Aug-11-23	Initiated	BofA Securities	Buy
Jul-27-23	Initiated	Scotiabank	Sector Perform
May-17-23	Initiated	BTIG Research	Buy
Jan-31-23	Initiated	Stifel	Buy
Jul-12-22	Initiated	Cantor Fitzgerald	Overweight
Feb-15-22	Initiated	Jefferies	Buy
May-05-21	Resumed	Credit Suisse	Outperform
Apr-26-21	Resumed	Credit Suisse	Outperform
Dec-07-20	Reiterated	H.C. Wainwright	Buy
Dec-03-20	Initiated	Stifel	Buy
Nov-05-20	Downgrade	Piper Sandler	Overweight → Neutral
Jul-07-20	Initiated	Credit Suisse	Outperform
May-05-20	Initiated	Barclays	Overweight
Jul-18-19	Initiated	Deutsche Bank	Buy
Nov-09-18	Initiated	Piper Jaffray	Overweight
Aug-01-18	Initiated	H.C. Wainwright	Buy
Oct-13-16	Resumed	Leerink Partners	Outperform
Jan-22-16	Initiated	JMP Securities	Mkt Outperform
Dec-30-15	Initiated	Oppenheimer	Outperform
Dec-16-15	Initiated	Citigroup	Buy

View All

Kura Oncology Inc Stock (KURA) Latest News

Kura Oncology to Report First Quarter 2024 Financial Results

GlobeNewswire Inc.

Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

GlobeNewswire Inc.

Kura Oncology to Participate in Stifel Targeted Oncology Forum

GlobeNewswire Inc.

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

GlobeNewswire Inc.

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc.

Kura Oncology Inc Stock (KURA) Financials Data

Kura Oncology Inc (KURA) Net Income 2024

KURA net income (TTM) was -$152.63 million for the quarter ending December 31, 2023, a -12.36% decrease year-over-year.

Kura Oncology Inc (KURA) Cash Flow 2024

KURA recorded a free cash flow (TTM) of -$124.99 million for the quarter ending December 31, 2023, a -12.92% decrease year-over-year.

Kura Oncology Inc (KURA) Earnings per Share 2024

KURA earnings per share (TTM) was -$2.08 for the quarter ending December 31, 2023, a -2.46% decline year-over-year.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in San Diego, California.